Go to the content. | Move to the navigation | Go to the site search | Go to the menu | Contacts | Accessibility

| Create Account

Falcini, FF. and Capannini, CS. and Martini, MG. and La Torre, LTF. and Vitale, VA. and Nacci, NF. and Matucci Cerinic, MCM. and Cimaz, CR. and Zulian, ZF. (2008) Mycophenolate Mofetil (MMF) for the treatment of juvenile onset systemic lupus erythematosus. [Conference papers] In: 15th Paediatric Rheumatology European Society (PreS) Congress, 14–17 September 2008, London, UK.

Full text disponibile come:

Documento PDF

Per gentile concessione di: http://www.ped-rheum.com/content/6/S1/P234

Abstract (english)


To evaluate the efficacy and safety of MMF in jo-SLE in a multicenter study.


Medical charts of 26 pts, 25 F, 1 M, mean age at SLE diagnosis 12.7 yrs (range 5–18), mean age at MMF starting 15.9 yrs (range 7.5–26.8), followed in Florence, Padua, and Messina, Italy, treated with MMF from 2004 to 2007, were retrospectively analyzed. Clinical and laboratory evaluation included: blood count, ESR, CRP, ANA, anti-dsDNA, LFT, coagulation, C4, renal function, Coombs' test, aCL, anti?2GPI and LAC at baseline and every 6 months. Disease activity was monitored by the SLEDAI score. Treatment duration was 24 ± 14.8 months (range 2–52). MMF (1.5–2 g/day) was started due to steroid toxicity (n = 9 pts), CyA toxicity (n = 5), disease activity (n = 8) or nephropathy progression despite previous immunosuppression (n = 4). 9/26 pts, before MMF had renal disease (7 WHO Class IIb, 1 Class III, 1 Class IV). In 5/9 MMF was the first treatment, while 4/9 had received immunosuppressants.


MMF was effective in reducing disease activity, steroid sparing in 14/26 (54%), stabilizing the disease in 8 (31%) and ineffective in 4 (15%). In 9/13 (69%) without renal involvement a good response was registered. Among pts with renal involvement, MMF was effective in 5/13 (38%), partially effective in 4 (31%) and ineffective in 4 (31%). 2 pts stopped MMF for diarrhoea and abdominal pain.


MMF seems to be effective and safe in jo-SLE, especially in patients without renal involvement. SLEDAI scores were significantly reduced at 6 and 12 months; p < 0.05.

Statistiche Download - Aggiungi a RefWorks
EPrint type:Conference papers (Presentazione)
Anno di Pubblicazione:2008
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/38 Pediatria generale e specialistica
Struttura di riferimento:Dipartimenti > pre 2012 - Dipartimento di Pediatria
Codice ID:1287
Depositato il:09 Dec 2008
Simple Metadata
Full Metadata
EndNote Format

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record